Biogen Anti-Tau Drug Slows Alzheimer's Decline
Two-year trial data show diranersen slowed cognitive decline by 38% in early Alzheimer's patients, with a Phase 3 trial still years away.
Updated on Nov. 17, 2026 in Alzheimer’s

Biogen presented two-year trial data for its anti-tau drug diranersen at a conference in Boston, reporting a 38% slowing of cognitive decline in early Alzheimer's patients. The lowest dose cuts levels of toxic tau protein in the brain.
Why it matters
Tau is a protein implicated in Alzheimer's progression, and a drug that slows decline over two years adds to the treatment options under study for a disease affecting about 55 million people globally. Biogen is discussing outlines of a Phase 3 trial with regulators.
The two-year data showed a gain of more than 1 point on the Clinical Dementia Rating-Sum of Boxes score and improvements in five of six cognition and function measures. The data did not include tau imaging, and no meaningful differences by age or sex were reported.
The players
Biogen
Biogen is a Cambridge, Massachusetts biotechnology company focused on neurological diseases, which is developing diranersen with partner Ionis Pharmaceuticals.
The details
Diranersen is designed to silence a gene that produces all forms of tau and was developed with Ionis Pharmaceuticals. The lowest dose is a 60-milligram spinal injection given twice a year, which Biogen said patients tolerate better than the 115-mg regimens. Reported side effects were mostly mild to moderate headache or back pain related to lumbar puncture, and a small number of patients experienced confusion.
Timeline
July 2026: Biogen reported 26% slowing at 18 months for the 60-mg dose.
November 17, 2026: Two-year diranersen data were presented in Boston.
Health Landscape
Diranersen arrives after amyloid-targeting drugs such as Leqembi began slowing decline by roughly 25% to 30%, and Biogen is weighing whether the two approaches could be used sequentially or in combination. Tau-targeting is a separate biological pathway that researchers have pursued as a complement to amyloid treatments.
For people with early Alzheimer's, a twice-yearly spinal injection under study could one day offer another option to slow decline, though it is not yet available. Current side effects in trials were mostly mild headache or back pain from the lumbar puncture procedure.
The takeaway
Early trial data suggest slowing tau may offer a complementary route to existing Alzheimer's treatments, but larger Phase 3 studies must confirm benefit before patients can expect access.
What happens next
Biogen is discussing outlines of a Phase 3 diranersen trial with regulators, though results are still several years away.
Further reading
For broader context on treatment advances, see Alzheimer’s coverage in the United States.






